121 related articles for article (PubMed ID: 10436782)
1. Imaging of pancreatic adenocarcinoma with radiolabeled monoclonal antibodies.
Mariani G
Ann Oncol; 1999; 10 Suppl 4():37-40. PubMed ID: 10436782
[TBL] [Abstract][Full Text] [Related]
2. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer.
Mariani G; Molea N; Bacciardi D; Boggi U; Fornaciari G; Campani D; Salvadori PA; Giulianotti PC; Mosca F; Gold DV
Cancer Res; 1995 Dec; 55(23 Suppl):5911s-5915s. PubMed ID: 7493369
[TBL] [Abstract][Full Text] [Related]
3. [Immunoscintigraphy of human pancreatic cancer an experimental study].
Jiang Y
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):198-201. PubMed ID: 8261865
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and pharmacokinetic screening in humans of monoclonal antibody AR-3 as a possible immunoscintigraphy agent in patients with pancreatic cancer.
Mariani G; Molen N; Bacciardi D; Boggi U; Bonino C; Costa A; Viacava P; Castagna M; Bodei L; Tarditi L
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):145-50. PubMed ID: 7632759
[TBL] [Abstract][Full Text] [Related]
5. [Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies].
Oriuchi N
Gan To Kagaku Ryoho; 1999 May; 26(6):762-7. PubMed ID: 10410144
[TBL] [Abstract][Full Text] [Related]
6. The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy.
Han S; Jin G; Wang L; Li M; He C; Guo X; Zhu Q
J Immunol Res; 2014; 2014():268479. PubMed ID: 24818166
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of monoclonal antibody 131I-B72.3 immunoscintigraphy of pancreatic adenocarcinoma xenografts in nude mice.
Kaufmann LW; Vaillant JC; van Gulik TM; van Royen EA; Parc R; Obertop H
Eur J Surg; 1999 Jul; 165(7):659-64. PubMed ID: 10452260
[TBL] [Abstract][Full Text] [Related]
8. Immunoscintigraphy and radioimmunotherapy in patients with pancreatic carcinoma.
Montz R; Klapdor R; Rothe B; Heller M
Nuklearmedizin; 1986 Dec; 25(6):239-44. PubMed ID: 3027672
[TBL] [Abstract][Full Text] [Related]
9. Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies.
Goldenberg DM
Am J Gastroenterol; 1991 Oct; 86(10):1392-403. PubMed ID: 1656726
[TBL] [Abstract][Full Text] [Related]
10. Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).
Peña Y; Perera A; Batista JF
MEDICC Rev; 2014; 16(3-4):55-60. PubMed ID: 25208121
[TBL] [Abstract][Full Text] [Related]
11. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer.
Chung YS; Sawada T; Kondo Y; Hirayama K; Inui A; Yamashita Y; Nakata B; Okamura T; Ochi H; Ho JJ; Kim YS; Sowa M
Jpn J Cancer Res; 1997 Apr; 88(4):427-34. PubMed ID: 9197537
[TBL] [Abstract][Full Text] [Related]
13. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.
Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I
J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
David KA; Milowsky MI; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Nanus DM; Bander NH
Clin Genitourin Cancer; 2006 Mar; 4(4):249-56. PubMed ID: 16729907
[TBL] [Abstract][Full Text] [Related]
15. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
Zhu H; Baxter LT; Jain RK
J Nucl Med; 1997 May; 38(5):731-41. PubMed ID: 9170438
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunodiagnosis of pancreatic cancer disease.
Klapdor R; Montz R
Int J Pancreatol; 1991; 9():99-111. PubMed ID: 1744454
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
18. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
[TBL] [Abstract][Full Text] [Related]
19. [Immunoscintigraphy and radioimmunotherapy of transplanted pancreatic carcinoma. Experimental animal studies with 131I-labeled monoclonal antibodies against CA 19-9, CEA and CA 125].
Klapdor R; Montz R; Greten H; Chatal JF; Douillard JY; Saccavini JC; Dietel M
Nuklearmedizin; 1985 Dec; 24(5-6):227-31. PubMed ID: 3867855
[TBL] [Abstract][Full Text] [Related]
20. Radiolabelled monoclonal antibodies in clinical and surgical oncology: a review.
Biassoni L; D'Andrea V; Biancari F; Santoni F; Dibra A; De Antoni E
Panminerva Med; 1997 Mar; 39(1):46-52. PubMed ID: 9175421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
